Prof. Meliha Nalçacı is a seasoned physician and educator with a long-standing commitment to medical excellence. She earned her medical degree from Istanbul University, Istanbul Faculty of Medicine in 1999 and has built a distinguished career combining clinical practice, teaching, and leadership. Throughout her career she has focused on delivering high-quality patient care while mentoring the next generation of physicians. In 2025 she joined Acibadem Health Group, where she continues to apply her expertise to improve patient outcomes and contribute to the institution’s clinical and educational missions. Known for her clinical rigor, compassionate approach, and dedication to lifelong learning, Prof. Nalçacı remains actively involved in professional development and collaborative care initiatives.
Education
- 1999 Istanbul University Istanbul Faculty of Medicine / Professor
- 1993 – 1999 Istanbul University Istanbul Faculty of Medicine, Department of Internal Medicine, Department of Internal Medicine / Associate Professor
- 1994 Istanbul University Istanbul Faculty of Medicine Hematology
- 1987 – 1993 Istanbul University Istanbul Faculty of Medicine, Department of Internal Medicine, Department of Internal Medicine / Research Assistant
- 1984 Istanbul University Istanbul Faculty of Medicine Internal Medicine
- 1980 Istanbul University Istanbul Faculty of Medicine
Experience
- 2025 Acibadem Health Group
Publications
- transfusion of blood and blood products
. clinical actual medicine internal medicine forum, 5(2), 55-61. (Control No: 4616984) NALÇACI MELİHA - The frequency of C609T polymorphism in the NQ01 gene and its relation to cytogenetic abnormalities in patients with myelodysplastic syndrome
celi mol biol, 30 (Publication No: 3213229) bağatır gülçin,SIRMA EKMEKÇİ SEMA,palandüz şükrü,ÖZTÜRK ŞÜKRÜ,ÇEFLE KIVANÇ,ÖZBEK UĞUR,YENEREL MUSTAFA NURİ,NALÇACI MELİHA - The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis
j elin med res, 8(1), 29- 39. (Publication No: 3213584) diral turkeys silk,mountains aday aynur,turkeys fehmi,akadam teker başak,yılmaz ceylan,NALÇACI MELİHA,YAVUZ AKİF SELİM,SARGIN FATMA DENİZ - Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia Long Term Follovv Up of 15 Cases
turk j haematol, Doi: 10.4274/tjh.2016.0086 (Publication No: 3213301) turkeys fehmi,diral turkeys silk,YENEREL MUSTAFA NURİ,NALÇACI MELİHA,KÜÇÜKKAYA REYHAN - Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
turk j haematol, 5(33), 94-101. (Publication No: 3213685) diral ipek,dağlar aday aynur,akadam teker başak,yılmaz ceylan,NALÇACI MELİHA,YAVUZ AKİF SELİM,SARGIN FATMA DENİZ - The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms.
J Clin Med Res, 7(3), 161-170. (Publication No: 1836377) silk from yonal turkeys,dağlar aday aynur,akadam teker basak.yılmaz ceylan,NALÇACI MELİHA,YAVUZ AKİF SELİM,SARGIN FATMA DENİZ - Prognostic significance of ASXL1 JAK2V617F mutations and JAK2V617F allele burden in Philadelphia negative myeloproliferative neoplasms
J Blood Med, 6, 157-171., Doi: doi: 10.2147/JBM.S78826. eCollection 2015. (Publication No: 1835326) silk from yonal turkeys,dağlar aday aynur,akadam teker basak.yılmaz ceylan,NALÇACI MELİHA,yavuz akif selim,sargın deniz - MPL W515L K Mutations in Chronic Myeloproliferative Neoplasms
TURK J HEMATOL, 30(1), 8-12. (Publication No: 1836709) AKPINAR TİMUR SELÇUK,HANÇER VEYSEL SABRİ,NALÇACI MELİHA,DİZ KÜÇÜKKAYA REYHAN - Revievv of therapeutic options and the management of patients with myelodysplastic syndromes.
EXPERT REV HEMATOL, 6(2), 165-189. (Publication No: 1836883) ÖZCAN MEHMET ALİ,İLHAN OSMAN,ÖZCEBE OSMAN İLHAMİ,NALÇACI MELİHA,GÜLBAŞ ZAFER
